Viewing Protocol Section

Home

Stocks

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

eRecord

Main Search All Studies All Organizations Report Bug

Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT04896008

Ignite Creation Date: 2024-05-06 @ 4:10 PM

Last Modification Date: 2024-10-26 @ 2:05 PM

Study NCT ID: NCT04896008

Protocol Section: NCT04896008

Start Identification Module Data

Expand Identification Module Data

Brief Title: A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality MK-7962-006ZENITH

Official Title: A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organization WHO Functional Class FC III or FC IV at High Risk Mortality

Acronym: ZENITH

Organization: Acceleron Pharma Inc a wholly-owned subsidiary of Merck Co Inc Rahway NJ USA

Organization Class: INDUSTRY

Organization Study ID: 7962-006

Secondary IDs

Secondary ID	Type	Domain	Link

A011-14	OTHER	None	None
MK-7962-006	OTHER	None	None
2021-001498-21	EUDRACT_NUMBER	Merck	None

Start Status Module Data

Status Verified Date: 2024-03

Overall Status: ACTIVE_NOT_RECRUITING

Study First Submit Date:

Study First Submit QC Date:

Last Update Submit Date:

Status:

Start Sponsor Collaborators Module Data

Investigator:

Lead Sponsor: Acceleron Pharma Inc a wholly-owned subsidiary of Merck Co Inc Rahway NJ USA

Lead Sponsor Class: INDUSTRY

Lead Sponsor: Acceleron Pharma Inc a wholly-owned subsidiary of Merck Co Inc Rahway NJ USA

Start Oversight Module Data

Description Module:

Study Last Update Post Date Type(Status Module):

Attachment: Upload